Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Precancerous ConditionInterventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: busulfan;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: peripheral blood stem cell transplantation;   Radiation: Total Body Irradiation (TBI);   Drug: Granulocyte colony-stimulating factor (G-CSF);   Drug: Phenytoin;   Drug: MethotrexateSponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)Recruiting - verified January 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials